Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| CervoMed Inc. | Trans sodium crocetinate (TSC) | Glioblastoma (GBM) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| CG Oncology, Inc. | Cretostimogene in combination with pembrolizumab - (CORE-008) | Intermediate-risk NMIBC | Phase 2 | Data Released | Intratumoral | Oncology |
| CG Oncology, Inc. | Cretostimogene - (BOND-003) | BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ | Phase 3 | Data Released | Intratumoral | Oncology |
| CG Oncology, Inc. | cretostimogene - (PIVOT-006) (EAP) | Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Ongoing | Intratumoral | Oncology |
| Channel Therapeutics Corporation | CC8464 (Oral) | Erythromelalgia | Phase 2a | Enrollment Initiation | Oral | Neurology |
| Checkpoint Therapeutics Inc. | Cosibelimab + Pemetrexed - (CONTERNO) | Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| Chemomab Therapeutics Ltd. | CM-101 | Liver Fibrosis | Phase 2a | Ongoing | Intravenous | Gastroenterology |
| Chemomab Therapeutics Ltd. | Nebokitug (CM-101) - (SPRING) | Primary Sclerosing Cholangitis | Phase 3 | Data Released | Intravenous | Gastroenterology |
